Chapter 2 Summary and Highlights
Chapter 3 Market Overview
- Introduction
- Definitions
- Neurons
- Central Nervous System
- Brain
- Spinal Cord
- Neurotransmitters
- Classification
- Progressive Ataxia and Weakness Disorders
- Friedreich's Ataxia
- Gertsmann-Straussler-Scheinker Disease
- Machado-Joseph Disease/Sca3
- Amyotrophic Lateral Sclerosis
- Hereditary Spastic Paraplegia
- Hereditary Neuropathies
- Multiple Sclerosis
- Diagnostic Tests for Progressive Ataxia and Weakness Disorders
- Diagnostic Tests for Multiple Sclerosis
- Diagnostic Tests for Amyotrophic Lateral Sclerosis
- Diagnostic Tests for Friedreich's Ataxia
- Diagnostic Tests for Machado-Joseph Disease
- Diagnostic Tests for Hereditary Spastic Paraplegia
- Diagnostic Tests for Hereditary Neuropathies
Chapter 4 Market Dynamics
- Introduction
- Market Drivers
- Progressive Ataxia and Weakness: Increasing Prevalence and Awareness
- Technological Advancements and Product Launch
- Increasing Expenditures for Health Care
- Rise in Alcohol and Drug Use
- Market Barriers
- Barriers to R&D for Progressive Ataxia
- Diagnostic Challenges
- Opportunities
- Advancements in Research and Technology
- Impact of Covid-19, Global Market for Treatment for Syndromes of Progressive Ataxia and Weakness Disorders
Chapter 5 Market Breakdown by Type and Technology
- Introduction
- Market by Type
- Market Overview
- Market Revenue
- Market by Technology
- Market Overview
- Market Revenue
- Small Molecule
- Market Overview
- Market Revenue
- Monoclonal Antibody
- Market Overview
- Market Revenue
- Others
- Biomarkers
- Gene Therapy
- Stem Cell
- Market Overview
- Market Revenue
Chapter 6 Market Breakdown by Disease
- Overview
- Market Revenue
- Market by Progressive Ataxia Diseases Type
- Friedreich's Ataxia
- Market Revenue
- Machado-Joseph Disease (Mjd)/Sca3
- Market Revenue
- Gertsmann-Straussler-Scheinker Disease
- Market Revenue
- Market by Disease Type
- Amyotrophic Lateral Sclerosis
- Progressive Bulbar Palsy
- Hereditary Spastic Paraplegia
- Hereditary Neuropathies (Hns)
- Multiple Sclerosis (Ms)
Chapter 7 Market Breakdown by Region
- Introduction
- North America
- The U.S.
- Canada
- Europe
- The UK
- Germany
- France
- Spain
- Italy
- Russia
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
- Rest of the World
Market Size and Forecast
Chapter 8 Market Breakdown by Distribution Channel
- Introduction
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
Chapter 9 Emerging Technologies and Developments
- Introduction
- Emerging Technology
- Stem Cell Therapy
- Gene Therapy
- Biomarkers
- Nasal Spray for Ms
- Disease-Modifying Therapies
- Rna-Based Therapies
- Conclusion
Chapter 10 Esg Development
- Introduction
- Esg Investments by Key Players
- Consumer Attitudes Towards Esg
- Conclusion
Chapter 11 Patent Analysis
Chapter 12 M&A and Venture Funding Outlook and Competitive Landscape
- Introduction
- Mergers, Acquisitions and Collaborations
- Strategic Initiatives
- Market Shares of Manufacturers of Progressive Ataxia and Weakness Disorders Drugs
Chapter 13 Company Profiles
- Abbott Laboratories
- Acorda Therapeutics Inc.
- American Regent Inc.
- Apotex Inc.
- Apotheca Inc.
- Astellas Pharma Inc.
- Astrazeneca GmbH
- Baxter International Inc.
- Bristol-Myers Squibb
- Eisai Co. Ltd.
- Eli Lilly and Company
- Gilead Sciences Inc.
- GlaxoSmithKline plc
- Glenmark Life Sciences
- Johnson & Johnson
- Merck Kgaa
- Novartis AG
- Pfizer Inc.
- Roche Holding Ltd.
- Sanofi
- Takeda Pharmaceutical Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
List of Tables
Summary Table A: Global Market for Treatments for Syndromes of Progressive Ataxia and Weakness Disorder Drugs, Through 2028
Summary Table B: Global Market for Progressive Ataxia and Weakness Disorders, Through 2028
Table 1: Classification, by Primary Dysfunction
Table 2: Drugs Approved in Europe for Multiple Sclerosis, 2011-2022
Table 3: Global Market for Drug Products for the Treatment of Neurodegenerative Dysfunctions, Through 2028
Table 4: Global Market for Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Technology, Through 2028
Table 5: Global Market for Small Molecule Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, Through 2028
Table 6: Global Market for Monoclonal Antibody Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, Through 2028
Table 7: Global Market for Other Technology Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, Through 2028
Table 8: Global Market for Drug Products for the Treatment of Progressive Ataxia, by Disease Type, Through 2028
Table 9: Global Market for Friedreich’s Ataxia Drugs, by Region, Through 2028
Table 10: Global Market for Machado-Joseph Disease (MJD) Drugs, by Region, Through 2028
Table 11: Global Market for Gerstmann-Straussler-Scheinker (GSS) Drugs, by Region, Through 2028
Table 12: Latest FDA Approvals for Amyotrophic Lateral Sclerosis
Table 13: Drugs in Clinical Trials for ALS, 2022
Table 14: Global Market for Amyotrophic Lateral Sclerosis Drugs, by Region, Through 2028
Table 15: Global Market for Progressive Bulbar Palsy (PBP) Drugs, by Region, Through 2028
Table 16: Global Market for Hereditary Spastic Paraplegia (HSP) Drugs, by Region, Through 2028
Table 17: Global Market for Hereditary Neuropathies Drugs, by Region, Through 2028
Table 18: Latest FDA Approvals for Multiple Sclerosis
Table 19: Global Market for Multiple Sclerosis (MS) Drugs, by Region, Through 2028
Table 20: Global Market for Progressive Ataxia and Weakness Disorders Drugs, by Region, Through 2028
Table 21: North American Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, Through 2028
Table 22: European Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, Through 2028
Table 23: Asia-Pacific Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, Through 2028
Table 24: Global Market for Progressive Ataxia and Weakness Disorders Drugs, by Distributive Channel, Through 2028
Table 25: Global Market for Progressive Ataxia and Weakness Disorders Drugs in Retail Pharmacy, by Region, Through 2028
Table 26: Global Market for Progressive Ataxia and Weakness Disorders Drugs in Hospital Pharmacy, by Region, Through 2028
Table 27: Global Market for Progressive Ataxia and Weakness Disorders Drugs in Online Pharmacy, by Region, Through 2028
Table 28: ESG Ranking of Major Players,2022
Table 29: ESG Investments, by Key Players, 2022
Table 30: ESG Trends, Major Players, 2021
Table 31: ESG Rankings for Major Companies, 2023
Table 32: CDP Scope Card for Major Players, 2022
Table 33: Patent Analysis, by Year, Jan. 2020 to March 2023
Table 34: Major Companies Patents: 2022 to March 2023
Table 35: M&A: Pharmaceutical Companies
Table 36: Abbott Laboratories: Annual Revenue, 2022
Table 37: Abbott Laboratories: News
Table 38: Abbott Laboratories.: Product Portfolio
Table 39: Acorda Therapeutics Inc.: News
Table 40: Acorda Therapeutics Inc.: Product Portfolio
Table 41: Eli Lily and Company: Annual Revenue, 2022
Table 42: Eli Lily and Company: News
Table 43: Eli Lily and Company: Product Portfolio
Table 44: GlaxoSmithKline PLC: Annual Revenue, 2022
Table 45: GlaxoSmithKline PLC: News
Table 46: GlaxoSmithKline PLC: Product Portfolio
Table 47: Glenmark Life Sciences: Annual Revenue, 2022
Table 48: Glenmark Life Sciences: Product Portfolio
Table 49: Novartis AG: Annual Revenue, 2022
Table 50: Novartis AG: News
Table 51: Novartis AG: Product Portfolio
Table 52: Pfizer Inc.: Annual Revenue, 2022
Table 53: Pfizer Inc.: News
Table 54: Pfizer Inc.: Product Portfolio
Table 55: Roche Holding Ltd.: Annual Revenue, 2022
Table 56: Roche Holding Ltd.: News
Table 57: Roche Holding Ltd.: Product Portfolio
Table 58: Sanofi: Annual Revenue, 2022
Table 59: Sanofi: News
Table 60: Sanofi: Product Portfolio
Table 61: Takeda Pharmaceutical Co. Ltd.: Annual Revenue, 2022
Table 62: Takeda Pharmaceutical Co. Ltd.: News
Table 63: Takeda Pharmaceutical Co. Ltd.: Product Portfolio
Table 64: Teva Pharmaceutical Industries LTD.: Annual Revenue, 2022
Table 65: Teva Pharmaceutical Industries LTD.: Product Portfolio
Table 66: Abbreviations
List of Figures
Summary Figure A: Global Market for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Summary Figure B: Global Market for Progressive Ataxia and Weakness Disorders, 2020-2028
Figure 1: Share of Global Health Expenditure Database, 2022
Figure 2: Global Market for Drug Products for the Treatment of Neurodegenerative Dysfunctions, 2020-2028
Figure 3: Global Market Shares of Drug Products for the Treatment of Neurodegenerative Dysfunctions, 2022
Figure 4: Global Market for Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Technology, 2020-2028
Figure 5: Global Market Shares of Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Technology, 2022
Figure 6: Global Market for Small Molecule Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, 2020-2028
Figure 7: Global Market for Monoclonal Antibody Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, 2020-2028
Figure 8: Global Market for Other Technology Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, 2020-2028
Figure 9: Global Market for Drug Products for the Treatment of Progressive Ataxia, by Disease Type, 2020-2028
Figure 10: Global Market Shares of Drug Products for the Treatment of Progressive Ataxia, by Disease Type, 2022
Figure 11: Global Market for Friedreich’s Ataxia Drugs, by Region, 2020-2028
Figure 12: Global Market for Machado-Joseph Disease (MJD) Drugs, by Region, 2020-2028
Figure 13: Global Market for Gerstmann-Straussler-Scheinker (GSS) Drugs, by Region, 2020-2028
Figure 14: Global Market for Amyotrophic Lateral Sclerosis Drugs, by Region, 2020-2028
Figure 15: Global Market for Progressive Bulbar Palsy (PBP) Drugs, by Region, 2020-2028
Figure 16: Global Market for Hereditary Spastic Paraplegia (HSP) Drugs, by Region, 2020-2028
Figure 17: Global Market for Hereditary Neuropathies Drugs, by Region, 2020-2028
Figure 18: Global Market for Multiple Sclerosis (MS) Drugs, by Region, 2020-2028
Figure 19: Global Market for Progressive Ataxia and Weakness Disorders Drugs, by Region, 2020-2028
Figure 20: Global Market Shares of Progressive Ataxia and Weakness Disorders Drugs, by Region, 2022
Figure 21: North American Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, 2020-2028
Figure 22: U.S. Market for Progressive Ataxia and Weakness Disorders Drug, 2020-2028
Figure 23: Canadian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 24: European Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, 2020-2028
Figure 25: UK Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 26: German Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 27: French Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 28: Spanish Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 29: Italian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 30: Russian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 31: Rest of European Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 32: Asia-Pacific Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, 2020-2028
Figure 33: Japanese Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 34: Chinese Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 35: Indian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 36: Australian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 37: Rest of Asia-Pacific Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 38: Rest of the World Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 39: Global Market for Progressive Ataxia and Weakness Disorders Drugs, by Distributive Channel, 2020-2028
Figure 40: Global Market for Progressive Ataxia and Weakness Disorders Drugs in Retail Pharmacy, by Region, 2020-2028
Figure 41: Global Market for Progressive Ataxia and Weakness Disorders Drugs in Hospital Pharmacy, by Region, 2020-2028
Figure 42: Global Market for Progressive Ataxia and Weakness Disorders Drugs in Online Pharmacy, by Region, 2020-2028
Figure 43: Benefits of Stem Cell Therapy for the Treatment of Syndrome of Progressive Ataxia and Weakness Disorders
Figure 44: Environmental, Social and Governance Factors in the Pharmaceutical Industry for Syndromes of Progressive Ataxia and Weakness Disorders Market
Figure 45: How A Strong ESG Proposition Benefits Pharmaceutical Business
Figure 46: Share of ESG-Geographical Adoption Level Across All Industries, 2022
Figure 47: Shares of Patents Registered/Approved, by Country, Jan. 2020 to July 2023
Figure 48: Global Progressive Ataxia and Weakness Disorders Drugs Market Shares, by Key Manufacturers, 2022
Figure 49: Abbott Laboratories: Annual Revenue, 2021 and 2022
Figure 50: Abbott Laboratories: Revenue Shares, by Business Unit, 2022
Figure 51: Abbott Laboratories.: Revenue Shares, by Region/Country, 2022
Figure 52: Eli Lily and Company: Annual Revenue, 2021 and 2022
Figure 53: Eli Lily and Company: Revenue Shares, by Business Unit, 2022
Figure 54: Eli Lily and Company: Revenue Shares, by Region/Country, 2022
Figure 55: GlaxoSmithKline PLC: Annual Revenue, 2021 and 2022
Figure 56: GlaxoSmithKline PLC: Revenue Shares, by Business Unit, 2022
Figure 57: GlaxoSmithKline PLC: Revenue Shares, by Region/Country, 2022
Figure 58: Glenmark Life Sciences: Annual Revenue, 2021 and 2022
Figure 59: Glenmark Life Sciences: Revenue Shares, by Business Unit, 2022
Figure 60: Novartis AG: Annual Revenue, 2021 and 2022
Figure 61: Novartis AG: Revenue Shares, by Business Unit, 2022
Figure 62: Novartis AG: Revenue Shares, by Region, 2022
Figure 63: Pfizer Inc.: Annual Revenue, 2021 and 2022
Figure 64: Pfizer Inc.: Revenue Shares, by Business Unit, 2022
Figure 65: Pfizer Inc.: Revenue Shares, by Region/Country, 2022
Figure 66: Roche Holding Ltd.: Annual Revenue, 2021 and 2022
Figure 67: Roche Holding Ltd.: Revenue Shares, by Business Unit, 2022
Figure 68: Roche Holding Ltd.: Revenue Shares, by Region, 2022
Figure 69: Sanofi: Annual Revenue, 2021 and 2022
Figure 70: Sanofi: Revenue Shares, by Business Unit, 2022
Figure 71: Sanofi: Revenue Shares, by Region/Country, 2022
Figure 72: Takeda Pharmaceutical Co. Ltd.: Annual Revenue, 2021 and 2022
Figure 73: Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Business Unit, 2022
Figure 74: Takeda Pharmaceutical Company Limited: Revenue Shares, by Region/Country, 2022
Figure 75: Teva Pharmaceutical Industries LTD.: Annual Revenue, 2021 and 2022
Figure 76: Teva Pharmaceutical Industries LTD.: Revenue Shares, by Business Unit, 2022
Figure 77: Teva Pharmaceutical Industries LTD.: Revenue Shares, by Region, 2022
